ADVA launches embedded timing solution for third-party hardware
2.11.2021 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today introduced its OSA 5400 SyncModule™ embedded timing solution, enabling technology suppliers to easily integrate precise synchronization into their hardware. The M.2 form factor module offers equipment vendors a way to simply and cost-effectively add crucial timing capabilities with key functionality into their switches, routers, open compute servers and other IT devices. Featuring GNSS, PTP and NTP engines as well as comprehensive PTP and GNSS monitoring and assurance functionality, the OSA 5400 SyncModule™ empowers third-party companies to leverage the unique expertise of ADVA’s Oscilloquartz synchronization specialists. The solution will provide a major boost to suppliers of mobile infrastructure and white box vendors. It will be key for enabling assured sub-microsecond timing in public and private networks as well as critical infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102005094/en/
ADVA’s new timing module enables technology manufacturers to easily embed synchronization capabilities into their devices (Photo: Business Wire)
“Our OSA 5400 SyncModule™ brings something completely new and very valuable to the market. For the first time, third-party technology manufacturers will be able to embed the most advanced synchronization capabilities into their designs and easily control them with our Ensemble Sync Director or their own management system,” said Gil Biran, general manager, Oscilloquartz, ADVA. “With our OSA 5400 SyncModule™, we’re extending the disaggregated approach to building networks into the area of synchronization. The integrated solution gives vendors the ability to instantly inject the most advanced, highly accurate and fully assured timing into their hardware platforms. As our solution utilizes the widely applied, standardized M.2 interface, integration is simple. It can also easily be added to existing designs.”
The trend towards network disaggregation is accelerating innovation and expanding the market for customers. This does, however, create a challenge for technology suppliers when it comes to synchronization. Now, the OSA 5400 SyncModule™ is filling that gap. The low-power M.2 module gives vendors of emerging technologies, such as open RAN and next-generation data center hardware, the ability to quickly harness the benefits of an integrated GNSS receiver, PTP, NTP and assurance engines, as well as full sync management functionality. Featuring multiple interface options for easy integration, the OSA 5400 SyncModule™ comes with an open API for simple configuration. It can also be managed by ADVA’s proven Ensemble Sync Director management system for complete control of the timing infrastructure.
“Cost-effective and hassle-free, our new embedded timing solution brings highly precise and assured synchronization to a whole new market. For companies who are suppliers of 5G RAN hardware or open compute servers, our OSA 5400 SyncModule™ offers major value,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Vendors like those, who are not necessarily experts in network timing, now have the opportunity to instantly pour all of our synchronization know-how into their solutions. And that enables customers to choose the ideal components for their specific needs complete with the best available timing.”
Watch this video to learn more about the OSA 5400 SyncModule™: https://youtu.be/iPUl_n0dvJU.
Further information is also available in these slides: https://adva.li/osa-5400-syncmodule-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005094/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
